Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | ATXN2 | Q99700 | 5/20 | 0.46 |
| ▸ | LIPE | Q05469 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22462930 | 0.90 | LIPE (0.46) | GPR119ENPP2DPP4EPHX2ATXN2 | |
| SCHEMBL13060199 | 0.86 | DPP4 (0.52) | GPR119DPP4 | |
| SCHEMBL16963415 | 0.84 | ENPP2 (0.58) | GPR119ENPP2DPP4EPHX2ATXN2 | |
| SCHEMBL2302258 | 0.84 | CARM1 (0.56) | GPR119ENPP2LIPE | |
| SCHEMBL22265504 | 0.82 | GPR119 (0.58) | GPR119DPP4 | |
| SCHEMBL30700557 | 0.79 | ENPP2 (0.46) | ENPP2EPHX2ATXN2 | |
| SCHEMBL16758967 | 0.78 | MGLL (0.54) | GPR119DPP4 | |
| SCHEMBL2951108 | 0.78 | GPR119 (0.63) | GPR119EPHX2LIPE | |
| SCHEMBL21723005 | 0.77 | ENPP2 (0.43) | ENPP2ATXN2 | |
| SCHEMBL30700799 | 0.76 | GPR119 (0.56) | GPR119EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023247670-A1 | NEW HETEROCYCLIC-CARBONYL-CYCLIC COMPOUNDS AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | GPR119 1935/4885ENPP2 3934/4885DPP4 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.